uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies.

Accept cookies Cookie Settings

View Notice

The buyer is not using this website to administer the notice. To record your interest or obtain additional information or documents please find instructions within the Full Notice Text. (NOTE: Contract Award Notices and Prior Information Notices do not normally require a response)

Add notice to my Sell2Wales Interest List

Notice Details

Title: SARS-COV-2 Vaccine Supply Agreement
Published by: The Department for Business, Energy and Industrial Strategy (BEIS)
Publication Date: 27/11/2020
Deadline Date:
Deadline Time:
Notice Type: Contract Award Notice
Has Documents: No
Has ESPD: No

Procurement of Novavax’s vaccine candidate NVX-CoV2373, as intended for the prophylaxis and vaccination against SARS-CoV-2 in humans.

Contract award notice

Results of the procurement procedure

Directive 2014/24/EU - Public Sector Directive

Directive 2014/24/EU

Section I: Contracting entity

I.1) Name and addresses

The Department for Business, Energy and Industrial Strategy (BEIS)

1 Victoria Street




Telephone: +44 2072155000



Internet address(es)

Main address:

I.4) Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

I.5) Main activity

General public services

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

SARS-COV-2 Vaccine Supply Agreement

Reference number: 4681/10/2020

II.1.2) Main CPV code



II.1.3) Type of contract


II.1.4) Short description

Procurement of Novavax’s vaccine candidate NVX-CoV2373, as intended for the prophylaxis and vaccination against SARS-CoV-2 in humans.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement

Value excluding VAT: 1.00 GBP

II.2) Description

II.2.3) Place of performance

NUTS code:


Main site or place of performance:


II.2.4) Description of the procurement

Procurement of Novavax’s vaccine candidate NVX-CoV2373, as intended for the prophylaxis and vaccination against SARS-CoV-2 in humans.

II.2.5) Award criteria


II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2.14) Additional information

Contract value is being withheld due to commercial sensitivity (Reg 50(6)(b) and (c)). Publication may enable competitors to calculate cost per dose. This will commercially prejudice:

(i) the supplier in its negotiations with other national governments; and

(ii) the contracting authority in negotiations with other vaccine vendors.

It may also impact fair competition between vaccine vendors.

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the Official Journal of the European Union

Justification for selected award procedure:

The works, supplies or services can be provided only by a particular economic operator for the following reason: protection of exclusive rights, including intellectual property rights


A direct contract with Novavax Inc. without competition is necessary for unforeseeable reasons of extreme urgency i.e. the urgent requirement to find a viable vaccine to end the Covid-19 pandemic (Regulation 32(2)(c)). In addition, competition was absent because Novavax has exclusive rights to this candidate vaccine (Reg 32(2)(b)(iii)).

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section V: Award of contract

Contract No: 4681/10/2020

Title: SARS-COV-2 Vaccine Supply Agreement

A contract/lot is awarded: Yes

V.2 Award of contract

V.2.1) Date of conclusion of the contract


V.2.2) Information about tenders

Number of tenders received: 1

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Novavax Inc.


21 Firstfield Road




NUTS: 00

The contractor is an SME: No

V.2.4) Information on value of the contract/lot (excluding VAT)

Total value of the contract/lot: 1.00 GBP

V.2.5) Information about subcontracting

Section VI: Complementary information

VI.3) Additional information

Contract end date is being withheld on grounds that release would be contrary to public interest (Reg 50(6)(a)) and commercial sensitivity (Reg 50(6)(b) and (c)). The date is variable based on production and delivery. Given significant challenges to overcome, the end date may set unrealistic expectation for the public/market. Also, given significant competition to bring to the market a successful vaccine, provision of the contract term is valuable information to competitors that may impact negotiations/future competition.

To view this notice, please click here:

Go reference: GO-20201123-PRO-17405639

VI.4) Procedures for review

VI.4.1) Review body

Department of Business, Energy and Industrial Strategy

1 Victoria Street, Westminister




VI.5) Date of dispatch of this notice


Information added to the notice since publication.

Additional information added to the notice since it's publication.
No further information has been uploaded.
Main Contact:
Admin Contact: N/a
Technical Contact: N/a
Other Contact: N/a

Commodity Categories

Commodity Categories
IDTitleParent Category
33651600VaccinesGeneral anti-infectives for systemic use and vaccines

Delivery Locations

Delivery Locations
100UK - All

Alert Region Restrictions

The buyer has restricted the alert for this notice to suppliers based in the following regions.

Alert Region Restrictions
There are no alert restrictions for this notice.

Copyright © Sell2Wales